[ad_1]
Nura Bio has raised a total of $140 million in a series A round after an extension. The start-up launched in 2020 with $73 million in financing. It specializes in small- molecule inhibitors of SARM1, a protein involved in Wallerian degeneration and that is thought to contribute to neurodegenerative conditions. In 2023, Nura started a Phase 1 trial for its lead molecule, NB-4746, which it says has neuroprotective effects in models of multiple sclerosis, traumatic brain injury, chemotherapy-induced peripheral neuropathy, and amyotrophic lateral sclerosis.
[ad_2]
Source link
